1681-15-8

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloropurine is used as an antiviral agent for its potential to combat viral infections, leveraging its chemical properties to interfere with viral replication mechanisms.
Used in Oncology Research:
In the field of oncology, 2-Chloropurine is used as an antitumor agent, where it may exhibit inhibitory effects on tumor growth, making it a candidate for cancer treatment development.
Used in Genetic Research:
2-Chloropurine is utilized as a mutagen in genetic research, where it is employed to induce mutations in bacterial and mammalian cells, facilitating studies on genetic variation and mutational effects.
Used in Chemical Synthesis:
2-Chloropurine is used as a precursor in the synthesis of nucleotide analogs, which are crucial for the development of new pharmaceuticals targeting specific biological processes and diseases.

InChI:InChI=1/C5H3ClN4/c6-5-7-1-3-4(10-5)9-2-8-3/h1-2H,(H,7,8,9,10)

Upstream product

• 5451-40-1 2,6-dichloro-7H-purine 
• 14631-08-4 2-chloro-4,5-diaminopyrimidine 
• 122-51-0 orthoformic acid triethyl ester 
• 14036-53-4 dimethoxymethyl acetate 
• 5404-88-6 1-(2-chloro-9H-purin-6-yl)hydrazine 
• 5451-40-1 2,6 dichloropurine 

Downstream Products

• 929028-84-2 2-chloro-9-(2,4-dichloro-benzyl)-9H-purine 
• 929028-85-3 2-chloro-7-(2,4-dichloro-benzyl)-7H-purine 
• 28128-16-7 2-iodopurine 
• 28128-15-6 2-bromopurine 
• 118807-48-0 2-chloro-9-phenyl-9H-purine 
• 1389318-45-9 tert-butyl (2-chloro-9H-purin-9-yl)(cyclohexyl)methylcarbamate 
• 1516608-93-7 ethyl 4-[2-chloro-9-(methoxymethyl)-9H-purin-8-yl]benzoate 
• 1516609-00-9 9-(methoxymethyl)-8-(4-methoxyphenyl)-2-[(4-methoxyphenyl)thio]-9H-purine 
• 1516608-63-1 9-(methoxymethyl)-2-[(4-methoxyphenyl)thio]-9H-purine 
• 455266-18-9 [1-(2-Phenyl-ethanesulfonyl)-piperidin-4-ylmethyl]-(9H-purin-2-yl)-amine 
• 1351087-93-8 4-(dimethylamino)-N-methyl-3-(1H-purin-6-ylamino)benzenesulfonamide 
• 1351087-96-1 N-methyl-4-(methyloxy)-3-(1H-purin-6-ylamino)benzenesulfonamide 
• 1383381-71-2 diethyl 9-[(N-(2-(trityloxy)ethyl)-N-(2-phosphonoethyl))-2-aminoethyl]-6-chloropurine 

Related news

On the mechanism of the two-way oxidation of 2-Chloropurine (cas 1681-15-8) by mammalian xanthine oxidase09/28/2019

2-Chloropurine is attacked by mammalian xanthine oxidase simultaneously at C-6 and C-8. The ratio of the two rates (=1) is insensitive to variations of pH or temperature. Experiments with 2-chloropurine as inhibitor indicate instantaneous association of this purine with the active center of the ...detailed

Relevant academic research and scientific papers

The synthesis of nebularine and its analogs via oxidative desulfuration in aqueous nitric acid

The synthesis of nebularine and its analogs has been achieved via oxidative desulfuration in H2O for the first time. With 50% HNO3as an oxidant and solvent, 18 products were obtained in good yields (70%–94%). The oxidative desulfuration system could tolerate different functional groups including fluoro, chloro, amino, alkyl, allyl, ribosyl, deoxyribosyl, and arabinofuranosyl groups.More importantly, the drug nebularine could be obtained successfully on a 20 g scale, which made this route more attractive for industrial applications.

Efficient synthesis of nebularine and vidarabine via dehydrazination of (hetero)aromatics catalyzed by CuSO4 in water

A simple dehydrazination reaction has been achieved in the presence of a catalytic amount of CuSO4 for the first time. With CuSO4 (2 mol%) as a catalyst and water as a solvent, the dehydrazination products were obtained in good yields (66-95%). Moreover, the drugs nebularine and vidarabine were afforded successfully, and vidarabine could be produced on a 0.923 kg scale, which shows good potential for industrial applications.

Reduction of different electron-poor N-heteroarylhydrazines in strong basic conditions

The first application of the Wolff-Kishner reduction methodology to electron-poor heteroaromatic compounds is reported. Hydrazino-containing heterocycles with hydrazone-type tautomery have been reduced under basic conditions. This novel chemistry was successfully applied to mono-dehalogenate a number of electron-poor heterocycles in a regioselective manner. According to the experimental results, this reductive process is a base-catalyzed reaction that takes only place in the presence of air, probably through an oxygen-assisted mechanism. As consequence of the specific features of this kind of hydrazone/enehydrazine tautomers, the overall outcome of the process is the synthesis of a Shapirotype reduction product by simply using a milder version of the Huang-Minlon methodology.

Core exploration in optimization of chemokine receptor CCR4 antagonists

The design, synthesis, and SAR studies of 'core' variations led to identification of novel, selective, and potent small molecule antagonist (22) of the CC chemokine receptor-4 (CCR4) with improved in vitro activity and liability profile. Compound 22 was e

Synthesis and properties of 2-guanidinopurines

2-Guanidinopurines were prepared as derivatives of 2,6-diamino-9-[2- (phosphonomethoxy)ethyl]-9H-purine (PMEDAP) (1), which shows an important antiviral activity. It completes earlier described synthesis of 6-guanidinopurine derivatives. The title compounds were obtained by the reaction of the corresponding 2-chloropurines with guanidine. 2- And 6-guanidinopurines were used as model compounds for determination of dissociation constants (pKa) of their ionogenic groups by capillary zone electrophoresis. The pKa values of ionogenic groups of the above compounds were compared with those of the corresponding aminopurines. The pKa of guanidino group at the purine moiety varies from 7.77 to 10.32. There is no protonation of N1-position in contrast to aminopurines. None of these compounds showed any antiviral activity.

Methods of treating insulin resistance syndrome and diabetes

This invention is directed to methods of treating insulin resistance syndrome and diabetes in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound derived from adenosine and analogues thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof, or a pharmaceutical composition comprising such compound.

Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties

A compound of the formula wherein K is N; Q is CH2or O; R6is hydrogen, alkyl, allyl, 2-methylallyl, 2-butenyl, or cycloalkyl where the nitrogen of the ring of X is substituted by Y; E is O or S; Y is hydrogen, alkyl, aralkyl, substituted aralkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, or substituted heterocyclylalkyl; and n and p are independently 0, 1, 2, or 3, provided that n+p is at least 1; T is hydrogen, alkyl, alkylcarbonyl, alkylthiocarbonyl, halo, carboxyl, A and B are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or OR′; or a pharmaceutically acceptable salt thereof, a pharmaceutic-ally acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.

Purine compounds having PDE IV inhibitory activity and methods of synthesis

The present invention comprises a method of synthesizing compounds having the formula (I): wherein: Z, R1, R2, R3, R4 and R8 are defined herein, which comprises the steps of (a) reacting a compound of the formula (II) wherein Q is a halogen, with an effec

Purine compounds having PDE IV inhibitory activity and methods of synthesis

The present invention comprises methods of synthesizing compounds having the formula I: wherein: Y1, Z, R1, R2, R3, R4 and R8 are as described herein, which comprises the steps of (a) reacting a compound of the formula III with a base to cause cyclization

2'-??4'-halo-?1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro?cyclopentane-1,7' (8'H)-?3H! imidazo?2,1-b!purin!-4' (5'H)-ones

Antihypertensive and bronchodilating phosphoclusterose inhibitory compounds of the formula STR1 or a pharmaceutically acceptable salt thereof wherein X is fluoro, chloro or bromo.